A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
The prevalence of dementia in the Western world in people over the age of 60 has been estimated to be greater than 5%, about two-thirds of which are due to Alzheimer's disease. The age-specific prevalence of Alzheimer's disease nearly doubles every 5 years after age 65, leading to a prevalence of greater than 25% in those over the age of 90 (ref. 3). Here, to search for low-frequency variants in the amyloid-β precursor protein (APP) gene with a significant effect on the risk of Alzheimer's disease, we studied coding variants in APP in a set of whole-genome sequence data from 1,795 Icelanders. We found a coding mutation (A673T) in the APP gene that protects against Alzheimer's disease and cognitive decline in the elderly without Alzheimer's disease. This substitution is adjacent to the aspartyl protease β-site in APP, and results in an approximately 40% reduction in the formation of amyloidogenic peptides in vitro. The strong protective effect of the A673T substitution against Alzheimer's disease provides proof of principle for the hypothesis that reducing the β-cleavage of APP may protect against the disease. Furthermore, as the A673T allele also protects against cognitive decline in the elderly without Alzheimer's disease, the two may be mediated through the same or similar mechanisms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nearly 30 LOAD susceptibility loci2-12 are known, and risk is significantly polygenic13.”
From Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease (2017) · cites this paper as [10]
In the citing paper
“Recent sequencing studies identified a number of genes that have rare variants associated with AD9-11,18-24.”
From Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease (2017) · cites this paper as [10]
In the citing paper
“The NH2-terminal APP A673T(Icelandic) mutation, however, makes APP a less favorable substrate for 𝛃 -secretase, resulting in decreased A 𝛃 production (299).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [299]
In the citing paper
“This observation is also true for the rare variant p.A673T (rs63750847) in APP, which was identified in Icelanders and was shown to have a strong protective effect against age-related cognitive decline as well as AD [43].”
From Genetics of Alzheimer’s disease: An East Asian perspective (2023) · cites this paper as [43]
In the citing paper
“The p.A673T variant was observed in control subjects aged over 85 years at a frequency of 0.45%, which is higher than that seen in AD patients [43].”
From Genetics of Alzheimer’s disease: An East Asian perspective (2023) · cites this paper as [43]
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,332
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876
A new multipoint method for genome-wide association studies by imputation of genotypes
Marchini, J., Howie, B., Myers, S., McVean, G., & Donnelly, P. (2007) · Nature Genetics · doi:10.1038/ng2088 · Cited by 2,609
Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study
Plassman, B. L., Langa, K. M., Fisher, G. G., Heeringa, S. G., Weir, D. R., Ofstedal, M. B., Burke, J. R., Hurd, M. D., Potter, G. G., Rodgers, W. L., et al. (2007) · Neuroepidemiology · doi:10.1159/000109998 · Cited by 1,932
MDS Cognitive Performance Scale(C)
Morris, J. N., Fries, B. E., Mehr, D. R., Hawes, C., Phillips, C., Mor, V., & Lipsitz, L. A. (1994) · Journal of Gerontology · doi:10.1093/geronj/49.4.m174 · Cited by 1,810
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Epidemiology of Alzheimer disease
Reitz, C., Brayne, C., & Mayeux, R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.2 · Cited by 1,675
Purification and cloning of amyloid precursor protein β-secretase from human brain
Sinha, S., Anderson, J. P., Barbour, R., Basi, G. S., Caccavello, R., Davis, D., Doan, M., Dovey, H. F., Frigon, N., Hong, J., et al. (1999) · Nature · doi:10.1038/990114 · Cited by 1,612
Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity
Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M., Brashler, J. R., Stratman, N. C., Mathews, W. R., Buhl, A. E., et al. (1999) · Nature · doi:10.1038/990107 · Cited by 1,438
Cited by
Items 801–900 of 1,008
Critical thinking on amyloid-beta-targeted therapy: challenges and perspectives
Sun, B., Chen, Y., Fan, D., Zhu, C., Zeng, F., & Wang, Y. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1810-y · Cited by 29
Sajad, M., Kumar, R., & Thakur, S. C. (2022) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2022.04.009 · Cited by 28
“Accumulation of Aβ in the brain occurs due to abnormal clearance (Jonsson et al., 2012) and enhanced activity of BACE (Panza et al.”
BackgroundPolygenic resilience scores capture protective genetic effects for Alzheimer’s disease
Hou, J., Hess, J., Armstrong, N. J., Bis, J. C., Grenier‐Boley, B., Karlsson, I., Leonenko, G., Numbers, K. T., O’Brien, E. K., Shadrin, A. A., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02055-0 · Cited by 27
“Notably, some genetic variants, such as APOE-ε2 [42] and the APP A673T variant [43], have been identified as protective for LOAD.”
BackgroundSelf-citationSandberg, A., Berenjeno‐Correa, E., Rodriguez, R. C., Axenhus, M., Weiss, S. S., Batenburg, K. L., Hoozemans, J. J. M., Tjernberg, L. O., & Scheper, W. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01141-1 · Cited by 31
“This notion is supported by genetic evidence from detrimental [3–6] and protective [7, 8] mutations in APP, and alterations in Aβ levels are instrumental for early diagnosis of AD [9].”
BackgroundCRISPR-Cas9 in Alzheimer’s disease: Therapeutic trends, modalities, and challenges
Chacko, L., Chaudhary, A., Singh, B., Dewanjee, S., & Kandimalla, R. J. L. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103652 · Cited by 29
Next generation therapeutics for Alzheimer's disease
Bredesen, D. E., & John, V. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202307 · Cited by 30
“Reducing this ratio, whether by affecting BACE ( b -site APP cleaving enzyme) or other cleavage of APP, appears to mitigate the AD severity (Bredesen et al, 2010; Galvan et al, 2006; Jonsson et al, 2012).”
Small Molecules and Alzheimer’s Disease: Misfolding, Metabolism and Imaging
Patel, V., Zhang, X., Tautiva, N., Nyabera, A., Owa, O., Baidya, M., Sung, H., Taunk, P., Abdollahi, S., Charles, S., et al. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150504145646 · Cited by 25
Genetic and Nongenetic Variation Revealed for the Principal Components of Human Gene Expression
Goldinger, A., Henders, A. K., McRae, A. F., Martin, N. G., Gibson, G. C., Montgomery, G. W., Visscher, P. M., & Powell, J. E. (2013) · Genetics · doi:10.1534/genetics.113.153221 · Cited by 29
“…have been linked to oxidative metabolic dysfunction, due to oxidative damage to neurons (Browne et al. 1997; Mecocci et al. 2004; Rhein et al. 2009) and neuronal energy deficiency (Hoyer 1992) and also improper peptide processing that leads to the buildup of amyloid plaques (Jonsson et al. 2012).”
BackgroundPartial loss of CALM function reduces Aβ42 production and amyloid deposition in vivo
Kanatsu, K., Hori, Y., Takatori, S., Watanabe, T., Iwatsubo, T., & Tomita, T. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw239 · Cited by 25
Coarse‐grained and All‐atom Simulations towards the Early and Late Steps of Amyloid Fibril Formation
Chiricotto, M., Tran, T. T., Nguyen, P. H., Melchionna, S., Sterpone, F., & Derreumaux, P. (2016) · Israel Journal of Chemistry · doi:10.1002/ijch.201600048 · Cited by 26
Ulstein, I. D., & Bøhmer, T. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160393 · Cited by 25
“Genetic studies have also identified several risk genes [4] and protective genes [5], adding to the complexity of AD etiology.”
BackgroundLu, M., Ji, W., Xu, D.-E., Yao, P.-P., Zhao, X., Wang, Z., Fang, L., Huang, R., Lan, L.-J., Chen, J.-B., et al. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.09.012 · Cited by 26
Decreased plasma C‐reactive protein levels in APOE ε4 allele carriers
Martiskainen, H., Takalo, M., Solomon, A., Stančáková, A., Marttinen, M., Natunen, T., Haapasalo, A., Herukka, S., Kuusisto, J., Soininen, H. S., et al. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.639 · Cited by 25
“This view recently gained further support from the identification of a protective APP variant (A673T), which was later shown to reduce Ab levels and protect against cognitive decline.(9,10) Physiologic functions of Ab are not well-established, but significant lines of evidence suggest that Ab may have potential protec…”
BackgroundGene mutation defends against Alzheimer’s disease
Callaway, E. (2012) · Nature · doi:10.1038/487153a · Cited by 25
Semagacestat's fall: where next for AD therapies?
(2013) · Nature Medicine · doi:10.1038/nm.3365 · Cited by 24
Schreiber, M. A., Bird, T. D., & Tsuang, D. W. (2014) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-014-0026-x · Cited by 25
“In a study interrogating large Icelandic WGS data [23], a predicted A673T change in APP reduced both the risk of AD and of cognitive decline in older subjects without AD.”
Watamura, N., Sato, K., Shiihashi, G., Iwasaki, A., Kamano, N., Takahashi, M., Sekiguchi, M., Mihira, N., Fujioka, R., Nagata, K., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm6155 · Cited by 25
Farkas, S., Szabó, A., Török, B., Sólyomvári, C., Fazekas, C. L., Bánrévi, K., Correia, P., Chaves, T., & Zelena, D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.985424 · Cited by 31
Mild Cognitive Impairment: A Subset of Minor Neurocognitive Disorder?
Geda, Y. E., & Nedelská, Z. (2012) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e31826abc00 · Cited by 29
Wang, H., Dey, D., Carrera, I., Minond, D., Bianchi, E., Xu, S., & Lakshmana, M. K. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.476689 · Cited by 28
“Additionally, it was discovered recently that the A673T coding mutation in APP protects significantly against memory decline in patients with AD as well as in the normally aging population by decreasing A levels (3).”
BackgroundRho Guanine Nucleotide Exchange Factor ARHGEF17 Is a Risk Gene for Intracranial Aneurysms
Yang, X., Li, J., Fang, Y., Zhang, Z., Jin, D., Chen, X., Zhao, Y. E., Li, M., Huan, L., Kent, T. A., et al. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.117.002099 · Cited by 28
Matrone, C., Iannuzzi, F., & Annunziato, L. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.04.003 · Cited by 25
Dreaming of a New World Where Alzheimer’s Is a Treatable Disorder
Catania, M., Giaccone, G., Salmona, M., Tagliavini, F., & Fede, G. D. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00317 · Cited by 29
How understudied populations have contributed to our understanding of Alzheimer’s disease genetics
Dehghani, N., Brás, J., & Guerreiro, R. J. (2021) · Brain · doi:10.1093/brain/awab028 · Cited by 25
Peptides Derived from Growth Factors to Treat Alzheimer’s Disease
Gascon, S., Jann, J., Langlois-Blais, C., Plourde, M., Lavoie, C. L., & Faucheux, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116071 · Cited by 25
“Furthermore, the amyloid hypothesis is also strongly supported by the identification of protective mutation of APP that results in lifelong decrease in APP cleavage into Aβ and reduced risk of AD [13].”
BackgroundBACE Inhibitor Clinical Trials for Alzheimer’s Disease
Watkins, E. A., & Vassar, R. J. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231258 · Cited by 25
Wallace, J. (2014) · Cell Calcium · doi:10.1016/j.ceca.2014.02.005 · Cited by 24
Diomede, L., Romeo, M., Cagnotto, A., Rossi, A., Beeg, M., Stravalaci, M., Tagliavini, F., Fede, G. D., Gobbi, M., & Salmona, M. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.01.006 · Cited by 23
Protective Variants in Alzheimer’s Disease
Andrews, S. J., Fulton‐Howard, B., & Goate, A. (2019) · Current Genetic Medicine Reports · doi:10.1007/s40142-019-0156-2 · Cited by 28
Lloyd, G. M., Trejo‐Lopez, J. A., Xia, Y., McFarland, K. N., Lincoln, S., Ertekin‐Taner, N., Giasson, B. I., Yachnis, A. T., & Prokop, S. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-0891-3 · Cited by 24
Chaves, R. S., Tran, M., Holder, A. R., Balcer, A. M., Dickey, A. M., Roberts, E. A., Bober, B. G., Gutierrez, E., Head, B. P., Groisman, A., et al. (2021) · Journal of Neuroscience · doi:10.1523/jneurosci.2553-20.2021 · Cited by 27
BACE2: A Promising Neuroprotective Candidate for Alzheimer’s Disease
Yeap, Y. J., Kandiah, N., Nižetić, D., & Lim, K. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220867 · Cited by 27
“Furthermore, a study has revealed that a missense mutation in the A PP suppresses A production and reduces the risk of AD [8].”
BackgroundAge‐dependent NMDA receptor function is regulated by the amyloid precursor protein
Rajão‐Saraiva, J., Dunot, J., Ribera, A., Temido‐Ferreira, M., Coelho, J. E., König, S., Moréno, S., Enguita, F. J., Willem, M., Kins, S., et al. (2023) · Aging Cell · doi:10.1111/acel.13778 · Cited by 26
Huang, H., Zhu, Y., Liao, L., Gao, S.-H., Tao, Y. K., Fang, X., Lian, Y., & Gao, C.-Y. (2023) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2023.110735 · Cited by 24
Wang, S. R., Agarwala, V., Flannick, J. A., Chiang, C. W. K., Altshuler, D., Flannick, J. A., Manning, A. K., Hartl, C., Agarwala, V., Fontanillas, P., et al. (2014) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2014.03.019 · Cited by 31
Active DNA Aβ42 vaccination as immunotherapy for Alzheimer disease
Lambracht‐Washington, D., & Rosenberg, R. N. (2012) · Translational Neuroscience · doi:10.2478/s13380-012-0037-6 · Cited by 24
“In this study, a single mutation (A673T) within the amyloid precursor protein (APP) gene resulted in a 40% reduction of the β-secretase cleavage product of APP: Aβ1-42; and carriers of this rare mutation were protected against developing AD [8].”
Hamm, J. P., Ethridge, L. E., Shapiro, J. R., Pearlson, G. D., Tamminga, C. A., Sweeney, J. A., Keshavan, M. S., Thaker, G. K., & Clementz, B. A. (2013) · Bipolar Disorders · doi:10.1111/bdi.12110 · Cited by 24
“Conversely, some ERPs marking affective disturbance could index resilience to psychosis (40) and thus be at least normal in BDNP(+) while being deviant in BDNP(–) and BDP, capturing important etiological variance and predictive power (41).”
Iron is a specific cofactor for distinct oxidation- and aggregation-dependent Aβ toxicity mechanisms
Ott, S., Dziadulewicz, N., & Crowther, D. C. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.019042 · Cited by 24
“…mutations that favour aggregation-prone isoforms of Aβ (Goate et al., 1991; Levy-Lahad et al., 1995; Li et al., 1995; Rogaev et al., 1995; Sherrington et al., 1995; Suzuki et al., 1994) but also, conversely, disease risk is reduced by a mutation that slows peptide generation (Jonsson et al., 2012).”
Goch, W., & Bal, W. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170749 · Cited by 25
Low, J. D., Bartberger, M. D., Cheng, Y., Whittington, D., Xue, Q., Wood, S. J., Allen, J. R., & Minatti, A. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.01.056 · Cited by 23
Weaker N-Terminal Interactions for the Protective over the Causative Aβ Peptide Dimer Mutants
Sharma, B., Ranganathan, S. V., & Belfort, G. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00412 · Cited by 23
Evaluation of Animal Models by Comparison with Human Late-Onset Alzheimer’s Disease
Kim, B., Lim, H.-S., Kim, Y., Kim, Y. J., Koo, I., & Jeong, S. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1036-6 · Cited by 25
Genetic signature of human longevity in PKC and NF‐κB signaling
Ryu, S., Han, J., Norden‐Krichmar, T. M., Zhang, Q., Lee, S., Zhang, Z., Atzmon, G., Niedernhofer, L. J., Robbins, P. D., Barzilai, N., et al. (2021) · Aging Cell · doi:10.1111/acel.13362 · Cited by 24
“A rare variant (A673T) discovered in the well- known familial AD causal gene, amyloid precursor protein (APP), protects against AD, and related cognitive decline (Jonsson et al., 2012).”
BackgroundAsih, P. R., Chatterjee, P., Verdile, G., Gupta, V. B., Trengove, R. D., & Martins, R. N. (2014) · Neurodegenerative Disease Management · doi:10.2217/nmt.14.29 · Cited by 25
Li, M., Pehar, M., Liu, Y., Bhattacharyya, A., Zhang, S.-C., O'Riordan, K. J., Burger, C., D'Adamio, L., & Puglielli, L. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.06.021 · Cited by 23
Self-citationHochard, A., Oumata, N., Bettayeb, K., Gloulou, O., Fant, X., Durieu, É., Buron, N., Porceddu, M., Borgne‐Sanchez, A., Galons, H., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121777 · Cited by 29
Hallé, M., Tribout-Jover, P., Lanteigne, A.-M., Boulais, J., St-Jean, J. R., Jodoin, R., Girouard, M., Constantin, F., Migneault, A., Renaud, F., et al. (2015) · Journal of Immunological Methods · doi:10.1016/j.jim.2015.05.002 · Cited by 25
Johnson, J. (2024) · Brain Circulation · doi:10.4103/bc.bc_86_23 · Cited by 31
“[59,60] In a study with 49 subjects, it was observed that the subjects with AD Stage 1 showed learning disabilities, and long‑term memory was affected significantly after 3 months.”
BackgroundMolecular Therapeutics in Development to Treat Alzheimer’s Disease
Tartaglia, M. C., & Ingelsson, M. (2024) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00738-6 · Cited by 25
Human stem cell models of dementia
Livesey, F. J. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu302 · Cited by 22
“More recently, disease-associated variants in TREM2 (32,33) and a coding variant in APP which protects individuals from AD (34) have been identified.”
BackgroundImpact of pre- and post-variant filtration strategies on imputation
Charon, C., Allodji, R. S., Meyer, V., & Deleuze, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-85333-z · Cited by 27
Chowdhury, S. R., Gu, J., Hu, Y., Wang, J., Lei, S., Tavallaie, M. S., Lam, C., Lü, D., Jiang, F., & Fu, L. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113541 · Cited by 23
GPR120 Signaling Controls Amyloid-β Degrading Activity of Matrix Metalloproteinases
Kikuchi, K., Tatebe, T., Sudo, Y., Yokoyama, M., Kidana, K., Chiu, Y. W., Takatori, S., Arita, M., Hori, Y., & Tomita, T. (2021) · Journal of Neuroscience · doi:10.1523/jneurosci.2595-20.2021 · Cited by 24
Zhou, W., Yang, J., Zhang, Y., Hu, X., & Wang, W. (2022) · MedComm · doi:10.1002/mco2.155 · Cited by 32
Afram, E., Lauritzen, I., Bourgeois, A., Manaa, W. E., Duplan, E., Chami, M., Valverde, A., Bauer, C., Pardossi‐Piquard, R., & Checler, F. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04737-4 · Cited by 26
Russ, T. C., Hamer, M., Stamatakis, E., Starr, J. M., Batty, G. D., & Mika Kivimaki, B. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.02.020 · Cited by 23
Liu, Y., Brossard, M., Sarnowski, C., Vaysse, A., Moffatt, M. F., Margaritte‐Jeannin, P., Llinares-López, F., Dizier, M., Lathrop, M. G., Cookson, W., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01058-y · Cited by 25
Self-citationDonner, L., Gremer, L., Ziehm, T., Gertzen, C. G. W., Gohlke, H., Willbold, D., & Elvers, M. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.06.015 · Cited by 25
A Report From the 8th Kuopio Alzheimer Symposium
Haapasalo, A., & Hiltunen, M. (2018) · Neurodegenerative Disease Management · doi:10.2217/nmt-2018-0029 · Cited by 25
Compact fibril-like structure of amyloid β-peptide (1–42) monomers
Barz, B., Buell, A. K., & Nath, S. (2021) · Chemical Communications · doi:10.1039/d0cc06607a · Cited by 23
Futai, E., Osawa, S., Cai, T., Fujisawa, T., Ishiura, S., & Tomita, T. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.629287 · Cited by 24
“Such mutations may be included in the rare protective variant of PS1 against Alzheimer disease, similar to the APP A673T mutation in the elderly Icelandic population (53).”
BackgroundThe double-edged role of copper in the fate of amyloid beta in the presence of anti-oxidants
Yang, J., Zhang, X., Zhu, Y., Lenczowski, E., Tian, Y., Yang, J., Zhang, C. M., Hardt, M., Qiao, C., Tanzi, R. E., et al. (2017) · Chemical Science · doi:10.1039/c7sc01787a · Cited by 22
Prions: A Piece of the Puzzle?
Lahiri, D. K. (2012) · Science · doi:10.1126/science.337.6099.1172-a · Cited by 22
A standard model of Alzheimer’s disease?
Walker, L. C., Lynn, D. G., & Chernoff, Y. O. (2018) · Prion · doi:10.1080/19336896.2018.1525256 · Cited by 23
“lowers the likelihood of developing dementia [30] fosters optimism that, given the right treatment at the right time, success is possible.”
BackgroundNovel approaches to increase synaptic resilience as potential treatments for Alzheimer’s disease
Pham, A. Q., & Dore, K. (2023) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2022.03.032 · Cited by 21
The Role of Neprilysin and Insulin-Degrading Enzyme in the Etiology of Sporadic Alzheimer's Disease
Morito, T., Hashimoto, S., Takamura, R., Watamura, N., Kakiya, N., Fujioka, R., Mihara, N., Sekiguchi, M., Watanabe-Iwata, K., Kamano, N., et al. (2025) · Journal of Neuroscience · doi:10.1523/jneurosci.2152-24.2025 · Cited by 22
“…mutations in the APP and PSEN1/2 genes on A β metabolism (Tomita et al., 1997, 1998; Wisniewski et al., 1998; Chen et al., 2012; De Strooper and Voet, 2012; Jonsson et al., 2012; Obregon et al., 2012; Bamne et al., 2014; Li et al., 2016; Xu et al., 2016; Hsu et al., 2018; Schilling et al., 2023).”
Interaction between variants in CLU and MS4A4E modulates Alzheimer's disease risk
Ebbert, M., Boehme, K. L., Wadsworth, M. E., Staley, L. A., Initiative, A. D. N., Mukherjee, S., Crane, P. K., Ridge, P. G., & Kauwe, J. S. K. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.08.163 · Cited by 26
Gong, M., Ye, S., Li, W., Zhang, J., Liu, Y., Zhu, J., Lv, W., Zhang, H., Wang, J., Lü, A., et al. (2020) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00070.2019 · Cited by 24
Self-citationGenetic testing in dementia‐A medical genetics perspective
Huq, A. J., Sexton, A., Lacaze, P. A., Masters, C. L., Storey, E., Velakoulis, D., James, P. A., & Winship, I. (2021) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5535 · Cited by 24
“therefore, only causing AD in biallelic that is, autosomal recessive form.(42,43)”
BackgroundVillaseca, P., Cisternas, P., & Inestrosa, N. C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1021796 · Cited by 22
“Interestingly, molecular genetics studies in Iceland (42) identified coding variants in the APP that were tested for an association with AD, after studying whole-genome sequencing of 1,795 subjects.”
BackgroundResultThe Amyloid Cascade Hypothesis 2.0: Generalization of the Concept
Volloch, V., & Rits‐Volloch, S. (2022) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-220079 · Cited by 22
“0 (sX = iA produced independently of A PP), the best way to inactivate the AD Engine is to deplete iA to levels below those required for its activation and operation [2], the goal achievable by the activation of BACE1 and/or BACE2 and utilization of their A -cleaving activities (reviewed in [2]).”
BackgroundInfluentialWittrahm, R., Takalo, M., Kuulasmaa, T., Mäkinen, P. M., Mäkinen, P., Končarević, S., Fartzdinov, V., Selzer, S., Kokkola, T., Antikainen, L., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106140 · Cited by 22
“In 2012, a coding variant A673T (rs63750847) in APP was found to protect against AD and agerelated cognitive decline in the Icelandic population (32).”
InfluentialLian, Y., Jia, Y., Wong, J., Zhou, X., Song, W., Guo, J., Masters, C. L., & Wang, Y. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02324-4 · Cited by 25
Amyloid β-peptide and Alzheimer's disease
Allsop, D., & Mayes, J. (2014) · Essays in Biochemistry · doi:10.1042/bse0560099 · Cited by 32
“© 2014 Biochemical Society rare variant (A673T) of APP that actually protects against AD and age-related cognitive impairment by inhibiting proteolytic cleavage at the β-secretase site and reducing Aβ production [26].”
BackgroundStrömberg, K., Eketjäll, S., Georgievska, B., Tunblad, K., Eliason, K., Olsson, F., Radesäter, A., Klintenberg, R., Arvidsson, P. I., von Berg, S., et al. (2014) · FEBS Journal · doi:10.1111/febs.13103 · Cited by 24
Mateu, N., Ciordia, M., Delgado, Ó., Sánchez‐Roselló, M., Trabanco, A. A., Gool, M. V., Tresadern, G., Pérez‐Benito, L., & Fustero, S. (2015) · Chemistry - A European Journal · doi:10.1002/chem.201501662 · Cited by 23
BACE2 as a new diabetes target: a patent review (2010 – 2012)
Southan, C. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.780032 · Cited by 24
“A mutation in APP, A673T, was found to be protective against AD and age-related cognitive decline, acting via reduced beta-secretase cleavage [53].”
BackgroundSEPT8 modulates β-amyloidogenic processing of APP by affecting the sorting and accumulation of BACE1
Kurkinen, K. M. A., Marttinen, M., Turner, L. J., Natunen, T., Mäkinen, P. M., Haapalinna, F., Sarajärvi, T., Gabbouj, S., Kurki, M., Paananen, J., et al. (2016) · Journal of Cell Science · doi:10.1242/jcs.185215 · Cited by 26
“…in APP protects from Alzheimer’s-disease- and age-related cognitive decline by reducing BACE1-mediated cleavage of APP and/or producing less of the aggregation-prone Aβ40 containing the A→T variation at position 2 (Di Fede et al., 2009; Jonsson et al., 2012; Benilova et al., 2014;Das et al., 2016).”
BackgroundResultWang, Z., Dong, X., & Sun, Y. P. (2018) · Langmuir · doi:10.1021/acs.langmuir.8b02890 · Cited by 22
Rare non-coding variants are associated with plasma lipid traits in a founder population
Igartua, C., Mozaffari, S. V., Nicolae, D. L., & Ober, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-16550-8 · Cited by 22
Anatomical Landmarks and DAG Network Learning for Alzheimer’s Disease Diagnosis
Tian, Z., Cao, C., Wang, Z., Xu, G., & Qiao, J. (2020) · IEEE Access · doi:10.1109/access.2020.3037107 · Cited by 24
“Alzheimer’s disease (AD) is an increasingly prevalent neurodegenerative disease characterized by memory disorder, aphasia, disuse, blindness, executive dysfunction, personality and behavior changes [1], [2].”
BackgroundNazam, F., Shaikh, S., Nazam, N., Alshahrani, A., Hasan, G. M., & Hassan, M. I. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-021-04120-6 · Cited by 22
Jayadev, S. (2022) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001125 · Cited by 22
Prostate Cancer: Is It a Battle Lost to Age?
Vaidyanathan, V., Karunasinghe, N., Jabed, A., Pallati, R., Kao, C., Wang, A., Marlow, G., & Ferguson, L. R. (2016) · Geriatrics · doi:10.3390/geriatrics1040027 · Cited by 26
“Age is often considered an important non-modifiable risk factor for a number of diseases which include, but are not limited to neurodegenerative diseases such as age-specific Alzheimer’s disease [3]; cardiovascular diseases such as coronary heart disease, stroke [4,5], and hypertension [6]; and certain cancers [7,8] i…”
BackgroundZetterberg, H., Lautner, R., Skillbäck, T. B., Rosén, C., Shahim, P., Mattsson, N., & Blennow, K. (2014) · Advances in clinical chemistry · doi:10.1016/b978-0-12-800141-7.00005-x · Cited by 25
Lu, Z., Zhu, H., Knickmeyer, R. C., Sullivan, P. F., Williams, S., Zou, F., & Initiative, A. D. N. (2015) · Genetic Epidemiology · doi:10.1002/gepi.21932 · Cited by 22
“The mutation of APP (amyloid beta [A4] precursor protein) protects against AD and age-related cognitive decline [Jonsson et al., 2012].”
Rare Variants in PLXNA4 and Parkinson’s Disease
Schulte, E. C., Stahl, I. G., Czamara, D., Ellwanger, D. C., Eck, S. H., Graf, E., Mollenhauer, B., Zimprich, A. A., Lichtner, P., Haubenberger, D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079145 · Cited by 24
Tamayev, R., Akpan, N., Arancio, O., Troy, C. M., & D'adamio, L. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-60 · Cited by 23
“These observations are consistent with the recent findings that β-processing of APP, but not Aβ, triggers pathological modifications associated with AD in human neurons derived from both familial and sporadic AD cases [8] and that a mutation in APP that reduces the BACE1 cleavage of APP protect elderly individual from…”
ResultProtective genetic variants against Alzheimer's disease
Mariño, C., Malotaux, V., Giudicessi, A., Aguillon, D. F., Falla, D. S., Lopera, F. J., & Quiroz, Y. T. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00116-4 · Cited by 23
van Doorn, L. J. C. V. W., Simmelink, M. J. A., Haußmann, U., Klafki, H., Struyfs, H., Linning, P., Knölker, H., Twaalfhoven, H. A. M., Kuiperij, H. B., Engelborghs, S., et al. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13527 · Cited by 24
“In the non-amyloidogenic pathway APP is cleaved by asecretase leading to the production of sAPPa (Steiner et al. 2008; Jonsson et al. 2012; Cuchillo-Iba~nez et al. 2015).”
BackgroundUeno, T., Matsuoka, E., Asada, N., Yamamoto, S., Kanegawa, N., Ito, M., Ito, H., Moechars, D., Rombouts, F. J. R., Gijsen, H. J. M., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00359 · Cited by 22
Fu, Z., Crooks, E. J., Irizarry, B. A., Zhu, X. A., Chowdhury, S., Nostrand, W. E. V., & Smith, S. O. (2024) · Journal of Structural Biology · doi:10.1016/j.jsb.2024.108092 · Cited by 22
“For instance, while the protective A2T mutation (Jonsson et al., 2012) decreases the hydrophobicity of the N-terminus, the A2V mutation (Di Fede et al., 2009) increases the amyloidogenesis and neurotoxicity of the mutated A β peptide.”
BackgroundUlku, I., Leung, R., Herre, F., Walther, L., Shobo, A., Säftig, P., Hancock, M. A., Liebsch, F., & Multhaup, G. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107510 · Cited by 22
Tariot, P. N., Riviere, M., Salloway, S., Burns, J. M., Snædal, J., Borowsky, B., Lopez, C. L., Liu, F., Rouzade‐Dominguez, M., Cazorla, P., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14237 · Cited by 22
New Insights into Epigenetic and Pharmacological Regulation of Amyloid-Degrading Enzymes
Nalivaeva, N. N., Belyaev, N. D., & Turner, A. J. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1703-1 · Cited by 20
“Although the hypothesis still retains its credibility [3, 4]”
BackgroundBarnwell, E., Padmaraju, V., Baranello, R., Pacheco‐Quinto, J., Crosson, C. E., Ablonczy, Z., Eckman, E. A., Eckman, C. B., Ramakrishnan, V., Greig, N. H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091531 · Cited by 22
“The importance of Ab reduction to potentially mitigate AD is further reinforced by the recent identification of an APP variant that reduces AD risk and lowers Ab [13].”
BackgroundGenome research in pre-dementia stages of Alzheimer's disease
Moreno–Grau, S., & Ruiz, A. (2016) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2016.12 · Cited by 22
Cebers, G., Lejeune, T., Attalla, B., Soderberg, M., Alexander, R. C., Budd Haeberlein, S., Kugler, A. R., Ingersoll, E. W., Platz, S., & Scott, C. W. (2016) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2016.119 · Cited by 20
Somavarapu, A. K., Shen, F., Teilum, K., Zhang, J., Mossin, S., Thulstrup, P. W., Bjerrum, M. J., Tiwari, M. K., Szunyogh, D., Søtofte, P. M., et al. (2017) · Chemistry - A European Journal · doi:10.1002/chem.201703440 · Cited by 20
Non-conventional compounds with potential therapeutic effects against Alzheimer’s disease
de Castro, A. A., Soares, F. V., Pereira, A. F., Polisel, D. A., Caetano, M. S., Leal, D. H. S., da Cunha, E. F. F., Nepovimová, E., Kuča, K., & Ramalho, T. C. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1608823 · Cited by 21
“Interestingly, even the levels of Aβ reduction or BACE-1 inhibition convenient for illness modification remain unclear [63,64].”
Background
Metadata
- Authors
- Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., Hoyte, K., Gustafson, A., Liu, Y., Lu, Y., Bhangale, T., Graham, R. R., Huttenlocher, J., Bjornsdottir, G., Andreassen, O. A., Jönsson, E. G., Palotie, A., Behrens, T. W., Magnusson, O. T., Kong, A., Thorsteinsdottir, U., Watts, R. J., & Stefansson, K.
- Affiliations
- Genentech (US)
- deCODE Genetics (Iceland) (IS)
- University of Oslo (NO)
- Karolinska Institutet (SE)
- University of Helsinki (FI)
- ORCID
- Venue
- Nature
- Published
- 2012-07-11
- Volume
- 488
- Issue
- 7409
- Pages
- 96-99
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2154755614
- Cited by
- 1,738
- References
- 26
- Citations by year
- 2026: 56 · 2025: 72 · 2024: 93 · 2023: 94 · 2022: 70 · 2021: 120 · 2020: 134 · 2019: 107 · 2018: 134 · 2017: 145 · 2016: 155 · 2015: 166 · 2014: 173 · 2013: 154 · 2012: 60
- FWCI
- 119.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Hirsla (Landspítali University Hospital) (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HL-102924, HL-102925, HL 103010, HL-102926)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- Alzheimer's disease, amyloid precursor protein, APP gene, protective genetic variants, cognitive decline in older adults, amyloid plaques, β-cleavage, amyloidogenic peptides, genetic risk, Icelandic population
- MeSH terms
- Aging, Alleles, Alzheimer Disease, Cognition, Cognition Disorders, Humans, Mutation, Aspartic Acid Endopeptidases, Amyloid beta-Protein Precursor, Genetic Predisposition to Disease, Amyloid Precursor Protein Secretases, HEK293 Cells, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.